News summarySeeking AlphaNov 6, 2026, 04:55 AM
Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental tests
Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental tests(摘要待生成)